iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Lupin Soars: Q3 Revenue Up 20%, Net Profit Quadruples to ₹613 Crore

8 Feb 2024 , 12:08 PM

Lupin Ltd. said on February 7 that its consolidated net profit for the October–December quarter of the current fiscal year increased by ₹300 Crore year over year to ₹613 Crore.

For the same time last year, the company reported a profit of ₹157.6 Crore.

Revenue increased to ₹5,197.4 Crore from ₹4,322.2 Crore in the same quarter last year.

Driven by robust growth across geographies, the company posted its biggest quarterly revenues to date and crossed the ₹5,000 Crore mark for the first time, according to a statement.

Profits before interest, taxes, depreciation, and amortization (EBITDA) for the company were ₹1,037.9 Crore, a 95% increase from ₹532.7 Crore during the same period last year. Compared to the same period last year, the EBITDA margin was ₹20 Crore.

'The U.S. continues to do well driven by demand for both in-line products and new launches,' said Nilesh Gupta, Managing Director of Lupin Limited, in response to the results. 'The India business continues to grow ahead of market with strong growth across our key therapies.' Our good performance has been aided by this favourable growth momentum, cost-cutting strategies, and operational leverage.

With sales of ₹1888.5 Crore in Q3 FY2024, North America accounted for 37% of Lupin's global sales, up from ₹ 1866.6 Crore in Q2 FY2024 and from ₹ 1527.1 Crore in Q3 FY2023.

India accounted for 34% of Lupin's worldwide sales in Q3 FY2024 with sales of ₹1725.1 Crore, up 2% from ₹1691.5 Crore in Q2 FY2024 and 13.4% from ₹1521.3 Crore in Q3 FY2023.

In Q3 FY2024, Lupin invested ₹356.7 Crore (7% of sales) in R&D, up from ₹ 289.6 Crore (6.8% of sales) in Q3 FY2023.

The U.S. FDA approved 14 ANDAs for Lupin during the quarter.

For feedback and suggestions, write to us at editorial@iifl.com

Lupin Limited - Wikipedia

Related Tags

  • Lupin
  • Pharma
  • Q3
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Awfis IPO oversubscribed 4.19x on day two
23 May 2024|09:51 PM
Indian markets end the day on high
23 May 2024|03:59 PM
Markets surge

Markets surge

Whatsapp
Facebook
Twitter
LinkedIn
23 May 2024|03:45 PM
MG Motor India to supply 3000 EVs to Vertelo
23 May 2024|03:46 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.